Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the p...
TN-301 First-in-Human Phase 1 Clinical Trial Results and Preclinical Combination Data to be Presented at Heart Failure Society of America Annual Scientific Meeting TN-201 Interim Seroprevalence Study Data and Phase 1b Clinical Trial Design to be Featured at Hypertrophic Cardiomyopathy Med...
2023-09-08 17:10:24 ET Gainers: Vigil Neuroscience ( NASDAQ: VIGL ) +7% . Tenaya Therapeutics ( TNYA ) +4% . CorMedix ( CRMD ) +4% . Xeris Biopharma ( XERS ) +3% . Avidity Biosciences ( RNA ) +3% . Losers: The L...
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that ...
2023-08-10 14:19:24 ET Tenaya Therapeutics press release ( NASDAQ: TNYA ): Q2 GAAP EPS of -$0.45. As of June 30, 2023, cash, cash equivalents and investments in marketable securities were $151.6 million. For further details see: Tenaya Therapeutics GAAP EPS of -$...
Dosing of First Patient in Phase 1b Trial of TN-201 On Track to Occur in Q3 2023 Data from Phase 1 Clinical Trial of TN-301 Accepted for Presentation at HFSA 2023 IND Application for TN-401 Anticipated in Second Half 2023 Second Quarter Cash and Investments of $152 Milli...
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that ...
2023-07-21 04:18:15 ET Summary Tenaya Therapeutics specializes in developing gene therapies and small molecules for heart diseases, focusing on genetic origins and precision medicine. TNYA's promising gene therapy candidate, TN-401, designed for ARVC due to PKP2 mutations, has sho...
2023-05-10 17:37:31 ET Tenaya Therapeutics press release ( NASDAQ: TNYA ): Q1 GAAP EPS of -$0.43 beats by $0.15 . Cash and cash equivalents of $173.6M Research & Development (R&D) Expenses: R&D expenses for the quarter ended March 31, 2023, were $25.6 m...
TN-201 Received Fast Track Designation from the FDA Dosing Complete in Phase 1 Clinical Trial of TN-301; Data Expected in Second Half 2023 Renowned Researchers Drs. Christine Seidman and Alex Marson Join Scientific Advisory Board Announces Formation of Technical Advisory B...
News, Short Squeeze, Breakout and More Instantly...
Tenaya Therapeutics Inc. Company Name:
TNYA Stock Symbol:
NASDAQ Market:
Tenaya Therapeutics Inc. Website:
Kathy Ivey, Ph.D., Promoted to Senior Vice President, Research and Timothy Hoey, Ph.D., Transitions to Advisory Role Pediatric Cardiologist and Genetic Therapy Expert Barry J. Byrne, M.D., Ph.D., Joins Scientific Advisory Board Board Member Jin-Long Chen, Ph.D., Steps Down ...
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that ...
2024-06-10 07:30:04 ET William Blair analyst issues OUTPERFORM recommendation for TNYA on June 10, 2024 05:41AM ET. TNYA was trading at $3.64 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recomm...